Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR)

Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR)

Levilimab is anti-interleukin-6 receptor (IL6R) monoclonal antibody. The article presents data obtained during 24 weeks of the SOLAR phase III study.Objective: to confirm efficacy and safety of levilimab in combination with methotrexate (MTX) in patients with methotrexate resistant active rheumatoid...

Full description

Bibliographic Details
Main Authors: V. I. Mazurov, M. A. Korolev, A. M. Prystrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Kretchikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, Yu. N. Linkova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, A. V. Eremeeva, A. A. Lutckii
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2021-08-01
Series:Современная ревматология
Subjects:
levilimab
monoclonal anti-il-6 receptor antibody
rheumatoid arthritis
Online Access:https://mrj.ima-press.net/mrj/article/view/1164

Internet

https://mrj.ima-press.net/mrj/article/view/1164

Similar Items